Structure Therapeutics (NASDAQ: GPCR) and Novo Nordisk (NYSE: NVO) have one big thing in common: the desire to compete in the bustling market for obesity therapies. While the pre-revenue biotech is still a fledgling in the midst of its attempt to develop its first approved medicine, some recently released data suggests that Novo Nordisk might want to keep an eye out.

But the possibility of developing one decent drug is a far cry from becoming one of the world's largest and most powerful pharmaceutical businesses, like Novo Nordisk is. Is it even remotely possible for Structure Therapeutics to be as good of an investment as Novo Nordisk, never mind filling a similarly sized pair of shoes? Let's investigate.

If Structure Therapeutics is going to become the next Novo Nordisk, it'll need to win on Novo's home turf, cardiometabolic medicines, especially those indicated for treating diabetes and obesity. Then, it'll need to replicate similar wins at a larger scale at least a couple of times to build out a full product lineup, as well as a vastly larger pipeline than the two clinical-stage programs it currently has.

Continue reading

Source Fool.com